• Source: Dasotraline

Dasotraline (INN; former developmental code name SEP-225,289) is a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) that was under development by Sunovion for the treatment of attention-deficit hyperactivity disorder (ADHD) and binge eating disorder (BED). Structurally, dasotraline is a stereoisomer of desmethylsertraline (DMS), which is an active metabolite of the marketed selective serotonin reuptake inhibitor (SSRI) antidepressant sertraline (Zoloft).




Adverse Effects


In phase I clinical trials for attention deficit hyperactivity disorder, test subjects reported the following side effects:

Loss of appetite
Dehydration
Dry mouth
Nausea
Insomnia
Anxiety
Panic attacks
Headaches




History


In 2017, the U.S. Food and Drug Administration accepted Sunovion's New Drug Application (NDA) for review for the treatment of ADHD; however, the NDA was ultimately rejected citing the need for additional studies to determine efficacy and tolerability. In July 2019, Sunovion’s NDA for the treatment of BED was accepted with an expected action date of May 2020. In May 2020, Sunovion halted its drug development program for dasotraline, withdrawing both NDAs for ADHD and BED.




Law






= Finland

=
Dasotraline is completely unscheduled.




See also


Centanafadine
Indatraline
Lometraline
Tametraline




References






Further reading


Liming Shao Patent
US application 2007203111, Shao L, Wang F, Malcolm SC, Hewitt MC, Bush LR, Ma J, Varney MA, Campbell U, Engel SR, Hardy LW, Koch P, Campbell JE, "Cycloalkylamines as monoamine reuptake inhibitors", published 2007-08-30, assigned to Sepracor Inc.
Asymmetry Patent
US patent 7129378, Han X, Krishnamurthy D, Senanayake CH, Lu Z-H, "Method of preparing amine stereoisomers", published 2005-07-28, assigned to Apsinterm LLC

Kata Kunci Pencarian:

• Dasotraline
• Cocaine
• Desmethylsertraline
• Ketamine
• Venlafaxine
• Methylphenidate
• Chlorphenamine
• Sertraline
• Modafinil
• Centanafadine